Archiv
Archiv anzeigen:
bis


Thromboprophylaxis with Apixaban for Cancer Patients

David Green, MD, PhD reviewing Carrier M et al. N Engl J Med 2018 Dec 4

Venous thromboembolism occurred less frequently with the direct oral anticoagulant apixaban than with placebo.


Risk for Esophageal Cancer in Patients with Gastroesophageal Reflux

David H. Ilson, MD, PhD reviewing Maret-Ouda J et al. JAMA Oncol 2018 Nov

Risk decreases over time with antireflux surgery or medication.


Counseling Individuals with Sickle Cell Trait

David Green, MD, PhD reviewing Pecker LH and Naik RP. Blood 2018 Nov 29

Recommendations for reproductive counseling and newborn screening


Reversing Red Cell Aplasia After Allogeneic Stem Cell Transplantation

Michael E. Williams, MD, ScM reviewing Chapuy CI et al. N Engl J Med 2018 Nov 8

Administration of the anti-CD38 monoclonal antibody daratumumab restored erythropoiesis.


Acute Myeloid Leukemia Relapse After Allogeneic Stem Cell Transplantation

Michael E. Williams, MD, ScM reviewing Christopher MJ et al. N Engl J Med 2018 Oct 31

The immune-mediated effects of the allograft on residual leukemia cells influenced the pattern of relapse.


A Guideline to Prevent Infection in Adults with Cancer-Related Immunosuppression

Daniel Kaul, MD reviewing Taplitz RA et al. J Clin Oncol 2018 Oct 20

An updated joint guideline from ASCO and IDSA on antimicrobial prophylaxis for patients with neutropenia


Factoring Family History into Screening for Colorectal Cancer

Charles J. Kahi, MD, MS reviewing Leddin D et al. Gastroenterology 2018 Nov

First guideline to address screening in the setting of family history of nonhereditary CRC or adenoma


Drug-Eluting Metal Biliary Stents: Still a Work in Progress

Douglas G. Adler, MD, FACG, AGAF, FASGE reviewing Jang SI et al. Endoscopy 2018 Nov 9

Tumor size and stent patency were not improved compared with a non–drug-eluting metal stent.


Cessation of Screening for Colorectal Cancer in Older Adults

Charles J. Kahi, MD, MS reviewing Calderwood AH et al. Am J Gastroenterol 2018 Nov 2

Most older adults with normal screening colonoscopy are instructed to return for screening at ages older than guideline-recommended cutoffs.


Anticoagulant Therapy for Immune Thrombocytopenia

David Green, MD, PhD reviewing Balitsky AK et al. Blood 2018 Nov 8

A new risk-assessment tool identified patients who should receive treatment.


Archiv
Seite von 76
Editorial Member Board Empfehlungen

Prof. Dr. med. Beat Thürlimann

Brustzentrum St. Gallen
Kantonsspital St. Gallen

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Im «New England Journal of Medicine» sind wieder einige interessante, auch «practice changing» Publikationen erschienen.

Kommentar weiterlesen

Enzalutamide for Castration-Resistant PSA-Only Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Hussain M et al. N Engl J Med 2018 Jun 28, Smith MR. N Engl J Med 2018 Jun 28

Metastasis-free survival was significantly improved with enzalutamide versus placebo.


First-Line Atezolizumab for Metastatic Nonsquamous NSCLC

Anne S. Tsao, MD reviewing Socinski MA et al. N Engl J Med 2018 Jun 14

Adding atezolizumab to bevacizumab and chemotherapy improved survival in chemotherapy-naive patients with non–small-cell lung cancer, regardless of EGFR or ALK mutation status.


Cytoreductive Nephrectomy for Metastatic Kidney Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Méjean A et al. N Engl J Med 2018 Jun 3, Motzer RJ and Russo P. N Engl J Med 2018 Jun 3

Adding nephrectomy to standard sunitinib therapy did not improve survival in patients with poor- and intermediate-risk disease.


ASCO 2018 Report — Breast Cancer

William J. Gradishar, MD

Highlights of the latest treatments


Intensive Surveillance for Colorectal Cancer

David H. Ilson, MD, PhD reviewing Wille-Jørgensen P et al. JAMA 2018 May 22, Sanoff HK. JAMA 2018 May 22

More- versus less-frequent testing did not improve survival after curative treatment for patients with stage II–III disease.


Fewer Patients with Breast Cancer Require Chemotherapy

William J. Gradishar, MD reviewing Sparano JA et al. N Engl J Med 2018 Jun 3

Outcomes were noninferior with endocrine therapy alone versus chemo-endocrine therapy in patients with intermediate recurrence scores.


Chemotherapy for Isolated Locoregional Recurrence of Breast Cancer

Henry Mark Kuerer, MD, PhD, FACS reviewing Wapnir IL et al. J Clin Oncol 2018 Apr 10

Long-term results confirm a benefit for ER-negative but not ER-positive patients.


Neoadjuvant Nivolumab for Resectable Lung Cancer

Anne S. Tsao, MD reviewing Forde PM et al. N Engl J Med 2018 Apr 16

A major pathological response was seen in 45% of patients.


First-Line Nivolumab plus Ipilimumab for Advanced Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Hellmann MD et al. N Engl J Med 2018 Apr 16

Progression-free survival was improved versus chemotherapy for patients with high tumor mutation burden.


First-Line Lenvatinib vs. Sorafenib for Unresectable Hepatocellular Carcinoma

David H. Ilson, MD, PhD reviewing Kudo M et al. Lancet 2018 Feb 9, Reig M and Bruix J. Lancet 2018 Feb 9

Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.